- 3. (twice amended) The [animal] <u>rodent</u> of claim [2] <u>1</u> wherein the [molecule is] <u>DNA</u> <u>sequence encodes</u> syndecan -1.
- 4. (twice amended) The [animal] <u>rodent</u> of claim [2] <u>1</u> wherein the syndecan is expressed [preferentially] in the areas of the hypothalamus responsible for the regulation of body weight and energy balance.
- 5. (amended) The [animal] <u>rodent</u> of claim [4 having incorporated therein a construct including] <u>1 where the promoter is</u> a cytomegalovirus promoter or <u>functional</u> portion thereof [including] <u>and</u> the <u>CMV</u> intermediate/early enhancer.
- 6. (amended) The [animal] rodent of claim 1 having the genotype FVB/N-TgN(synd-1).

 Please cancel claims 7-9.
- 10. (twice amended) A method for screening for compounds which can alter body weight comprising:

administering a compound to a [non-human] transgenic [animal genetically engineered to express] rodent whose genome comprises a stably integrated DNA sequence encoding a syndecan [or proteoglycan portions thereof] operably linked to a promoter, wherein [the animal is characterized by an obese phenotype] expression of the DNA sequences results in the rodent developing maturity onset obesity [.], and

observing whether there is a change in body weight over a period of time.

Please cancel claim 11